

Discover Generics



Cost-Effective CT & MRI Contrast Agents



Voxel-Based Morphometry in Individual Patients: A Pilot Study in Early Huntington Disease

M. Mühlau, A.M. Wohlschläger, C. Gaser, M. Valet, A. Weindl, S. Nunnemann, A. Peinemann, T. Etgen and R. Ilg

This information is current as of June 25, 2025.

AJNR Am J Neuroradiol 2009, 30 (3) 539-543 doi: https://doi.org/10.3174/ajnr.A1390 http://www.ajnr.org/content/30/3/539

ORIGINAL RESEARCH

M. Mühlau A.M. Wohlschläger C. Gaser M. Valet A. Weindl S. Nunnemann A. Peinemann T. Etgen R. Ilg

Voxel-Based Morphometry in Individual Patients: A Pilot Study in Early Huntington Disease

BACKGROUND AND PURPOSE: Voxel-based morphometry (VBM) has proved a powerful method to detect subtle changes of gray matter (GM) at the group level but the role of VBM for the detection of GM changes in single subjects, especially in those with suspected neurodegenerative disorder, remains uncertain. Here, we performed single subject analyses in 22 patients in early stages of Huntington disease (HD), a neurodegenerative disorder with a well-known and characteristic pattern of GM loss.

MATERIALS AND METHODS: We applied an ANCOVA with age and gender as covariates and corrected for multiple statistical tests by false discovery rate (P < 0.05). Each patient was compared to 133 healthy controls. The same procedure was applied to 22 of the controls matched for age and gender in a pair-wise manner.

RESULTS: Our analyses yielded biologically plausible results in HD patients in which GM decrease within the caudate nucleus could be identified in 15 of the 16 most affected patients while GM decrease was found in only 1 control subject. Lowering the size of the control group yielded comparable results with 99 and 66 control subjects whereas sensitivity decreased with 33 control subjects.

CONCLUSIONS: Our pilot study demonstrates a potential role of VBM for the detection of cerebral GM changes in single subjects with suspected neurodegenerative disorder.

For the analysis of brain images from single patients with suspected neurodegenerative disorder, visual inspection is the method of choice. Inspection often causes the vague impression of a "borderline finding" that cannot be interpreted further because no statistical measures of the "suspicious region" are at hand. Addressing this problem, we aimed to obtain biologically plausible statistical parametric maps from single patients in early stages of a well-characterized neurodegenerative disorder.

For our project, we chose voxel-based morphometry (VBM) because this method had proved sensitive to detect subtle gray matter (GM) changes in numerous group studies on neuropsychiatric disorders, whereas only few attempts had been undertaken to detect GM changes in single subjects. These studies mainly focused on the automated detection of focal GM changes that can cause epilepsy¹⁻⁹ and demonstrated different degrees of sensitivity. One further study used VBM for the detection of lesions.¹⁰ Here, different VBM approaches were compared with "expert tracing" (of lesions). The "optimized approach" with unmodulated data¹¹ detected 8 of 10 lesions but delineated only 21% of the lesion volume, which was attributed to "the adverse influence of lesions on the preprocessing steps and to insufficient statistical power." Indeed, the control group consisted of only 19 subjects, though in an early description of VBM,¹² it had already been stated that, "even with many hundreds of subjects in a data base of controls, the method may not be powerful enough to detect subtle abnormalities in individuals." Another VBM study on autism

Received August 4, 2008; accepted after revision September 29.

DOI 10.3174/ajnr.A1390

successfully applied analyses at the single-subject level.¹³ Nevertheless, we are aware of only 1 VBM study that investigated single subjects with a neurodegenerative disease. Mummery et al¹⁴ studied 6 patients with semantic dementia by comparing each of them with 14 healthy control subjects and demonstrated GM decrease mainly in the left temporal pole.

To further investigate the potential role of VBM for single-subject analyses of GM decrease in early stages of neurodegenerative disorders, we tested different parametric approaches and used a relatively large control group. We chose patients with Huntington disease (HD) because this neurodegenerative, autosomal-dominant disorder results from an expanded CAG trinucleotide repeat within the IT15 gene located on chromosome 4¹⁵ so that it can certainly be diagnosed without MR imaging. HD usually presents with the clinical triad of involuntary movements, dementia, and behavioral disturbances. In HD, GM loss is most accentuated within the striatum and insular cortex, which has been demonstrated repeatedly so that the results derived from our analyses can be discussed with regard to biologic plausibility.¹⁶⁻²⁹

Materials and Methods

Patients

Data and images were derived from routine diagnostics of our HD outpatient clinic. The group consisted of 22 gene-positive subjects in early stages of HD (women, 12; CAG repeats: range, 40–48; mean \pm SD, 45 \pm 2; age range, 35–61 years; mean \pm SD, 44 \pm 8 years). The motor score of the Unified Huntington's Disease Rating Scale ranged from 0 (no motor symptoms in 3 patients) to 43 (considerable motor symptoms) with a mean value of 17 and an SD of 15.

Control Group

Images were derived from volunteers who had participated in imaging studies as healthy control subjects at our department. In these studies, subjects were interviewed before scanning by an experienced ORIGINAL RESEARCH

From the Departments of Neurology (M.M., A.M.W., M.V., A.W., S.N., A.P., T.E., R.I.), Nuclear Medicine (A.M.W.), and Neuroradiology (A.M.W.), Technische Universität München, Munich, Germany; and Department of Psychiatry (C.G.), University of Jena, Jena, Germany.

Please address correspondence to Mark Mühlau, MD, Department of Neurology, Technische Universität München, Ismaninger Str 22, 81675 Munich, Germany; e-mail: muehlau@lrz.tum.de

neurologist and were only included if there was no indication for any neurologic or psychiatric disorder. Moreover, all images were screened by an experienced neuroradiologist and were excluded if there were unusual or abnormal findings. We could recruit the images of 133 subjects (women, 62; age range, 27–74 years; mean \pm SD, 55 \pm 12 years).

Matched Control Subjects

Of the 133 control subjects, we chose 22 matched control subjects (ie, 1 matched control subject per patient). For each patient, the control of the same sex with the age closest to the respective patient was chosen (age differences: <1 year, 13 pairs; 1–2 years, 6 pairs; 2–3 years, 2 pairs; 5 years, 1 pair).

MR Imaging Acquisition

Each subject underwent MR imaging in the same scanner (magnetic field intensity, 1.5T; scanner, Magnetom Symphony [Siemens, Erlangen, Germany]; sequence, T1 magnetization-prepared rapid acquisition of gradient echo; TR, 11.1 ms; TE, 4.3 ms; TI, 800 ms; voxel size, $1 \times 1 \times 1 \text{ mm}^3$; flip angle, 15°; sagittal sections, 160; FOV, 256 × 256 mm).

Which Statistical Test Should Be Used?

We made no effort to apply nonparametric tests because, here, ranks are considered exclusively. The comparison of a single patient to a group of 133 control subjects can, at best, yield rank 134 for the patient corresponding to an uncorrected *P* value of 0.0075 (1/134), so that it seems very unlikely to provide results that remain significant after correction for multiple statistical tests as required for hypothesis-free whole-brain analyses. Instead, we tested 2 parametric approaches.³⁰ For both approaches, we assumed a *t* distribution of the data of the control group. With respect to the variance of the test "group" (containing only 1 subject), we tested 2 approaches:

The first approach is based on the assumption that the patient's value constitutes the mean value of a (hypothetical) population with a variance equal to that of the control group. This approach is implemented by default in most programs for the analyses of neuroimaging data such as statistical parametric mapping and has been the method of choice so far, though, to the best of our knowledge, this issue has never been discussed explicitly. This "conventional approach" corresponds to the 2-sample *t* test with the "pooled" estimate of variance and results in the following equation for the T value:

1)
$$T = \frac{\mu_c - \mu_p}{\sqrt{\sigma^2 (1/N_c + 1/N_p)}} \text{ with}$$
$$\sigma^2 = \frac{(N_c - 1)\sigma_c^2 + (N_p - 1)\sigma_p^2}{N_c + N_p - 2}$$

Here the common variance is calculated by weighting each group variance by the number of observations in that group, thus, giving more weight to larger groups (because they are better estimates). Given N_p is one, equation 1 reduces to

2)
$$T = \frac{\mu_c - \mu_p}{\sqrt{\sigma_c^2 / N_c + \sigma_c^2}}$$

The "alternative approach" does not assume any variance from the patient. Instead, the patient is regarded as a unique single case and, hence, is treated as a fixed effect. This complies with the 1-sample *t* test where a test value ρ (eg, from a patient) is compared with the values of



Fig 1. Overview on the percentage of patients with HD with regional GM decrease identified. The color bar in the right lower corner indicates the number (percentage) of patients where regional GM decrease could be identified by single-subject analyses. The number (percentage) is projected onto the normalized averaged T1-image. The numbers in the upper right corner indicate the MNI coordinates.

a sample of N controls with the mean value μ and the SD σ . The T value is estimated as follows:

3)
$$T = \frac{\mu - \rho}{\sqrt{\sigma_c^2 / N_c}}$$

Note that the 2-sample *t* test for unequal variances (Welch *t* test) does not apply because the degrees of freedom cannot be estimated.

It is obvious that the 2-sample t test (with a "pooled" estimate) of the conventional approach (equation 2) yields lower T values than the 1-sample *t* test of the alternative approach (equation 3) and is hence more conservative. It is noteworthy that this more conservative approach has also been suggested recently for the neuropsychologic assessment of single patients.³¹ However, both approaches are based on different statistical assumptions so that neither of them can primarily be regarded correct or incorrect. Accounting for the problem of statistical assumptions when comparing a single subject with a group, it has been proposed to empirically validate the statistical approach by comparing each healthy subject to the remainder and by relating these findings to the type 1 error probability.³² Applying a significance threshold of P less than .05 corrected, we expect to (erroneously) detect GM decrease in 5% of the healthy control subjects, that is in approximately 1 of the 22 matched control subjects analyzed in our study. More precisely, the number of matched control subjects with GM decrease identified should range from 0 to 3 (χ^2 test: P > .05).

Following the proposal of an empiric validation, we could clearly falsify the alternative approach on the basis of the 1-sample t test because it yielded GM decrease in every control subject. Therefore, we concentrated on the conventional approach on the basis of the 2-sample t test (with a "pooled" estimate of variance).



Fig 2. Results derived from ANCOVAs in 4 patients with HD. GM decrease of 4 patients with HD (1 patient per panel) is displayed by the maximum intensity projection (left side), by the projection onto the normalized averaged T1-image (middle) and, to enable visual inspection, by the individual T1-weighted image (right side). The numbers in the upper right corner indicate the MNI coordinates. All images are displayed with a significance threshold (voxel level) of P less than .05 corrected (FDR). In panel A, axial sections of HD patient 5 (motor score of the Unified Huntington's Disease Scale, 34; CAG repeats, 43; age, 48; sex, female) are shown. In this patient, global atrophy can be detected by visual inspection (right side). In panel B, axial sections of HD patient 3 (motor score of the Unified Huntington's Disease Scale, 37; CAG repeats, 48; age, 60; sex, female) are shown; here, visual inspection fails to detect GM decrease. In panel C, axial and coronal sections of HD patient 6 (motor score of the Unified Huntington's Disease Scale, 33; CAG repeats, 43; age, 51; sex, male) are shown; note that, besides decent GM loss nearly restricted to the striatum, the atrophy of the left temporal pole (in combination with an arachnoidal cyst) is also identified. In panel D, axial and coronal sections of HD patient 13 (motor score of the Unified Huntington's Disease Scale, 9; CAG repeats, 45; age, 36; sex, female) are displayed; here, cortical and striatal GM loss is of a similar degree.

Accounting for Age and Sex

Before our study, we had made extensive attempts to generate statistical parametric maps of single subjects with various neuropsychiatric diseases compared with populations other than the one analyzed in this study. It is intriguing that when increasing the number of control subjects, we saw more significant and more plausible results at first. However, when including additional control subjects of ages more different from the subject under investigation, significance decreased. It is notable that significance increased again after accounting for age and sex. This is well conceivable because age and sex considerably influence regional and global GM values in healthy subjects.^{11,33,34} Therefore, we accounted for age and sex by including these parameters in our model and extended the 2-sample t test to an analysis of covariance (ANCOVA).

Preprocessing and Distributional Assumptions

For normalization and segmentation, default settings of VBM5 (http://dbm.neuro.uni-jena.de/), an extension of SPM5 (http://www. fil.ion.ucl.ac.uk/spm/software/spm5/), were applied. Apart from the unified segmentation as implemented in SPM5,35 VBM5 applies a hidden Markov random field model. ³⁶ This segmentation procedure minimizes the noise level by removing isolated voxels of 1 tissue class, which are unlikely to be a member of this tissue class. For smoothing, we used a Gaussian kernel of 12-mm full width at half maximum, which is necessary to fulfill the distributional assumptions of VBM, especially for the analysis of single subjects.³⁷

Voxels Included in the Analyses ("Explicit Masking")

We analyzed only voxels that were likely to represent GM according to the probability maps of SPM5 ("priors") for GM, white matter (WM), and CSF that have been derived from a large cohort of healthy control subjects. Therefore, a voxel was only included if it displayed a GM value greater than both the corresponding WM and CSF values. Accounting for the existence of another class apart from the 3 tissue classes, the background class, we also applied an absolute voxel threshold of a GM value greater than 0.2 (range, 0-1).

Correction for Multiple Statistical Tests

To correct for multiple statistical tests, we applied the false discovery rate (FDR) predicated on the procedure of Benjamini and Hochberg.^{38,39} We set a whole brain significance level of *P* less than .05.

No Systematic Shifts of MR Imaging Parameters with Time

All subjects underwent MR imaging examinations from September 2000 to September 2003 and were almost evenly distributed during the scanning period. In most VBM studies, the dates of MR imaging scans have assumingly also overlapped between the groups under investigation, though this is rarely stated explicitly. To certainly exclude that the statistical parametric maps of single subjects result from shifts of MR imaging parameters with time, we performed multiple regression analyses with the smoothed GM images. Here, the date of MR imaging and the age and sex of the subjects served as covariates. This analysis yielded age-related GM loss and sex-related differences in GM as described previously⁴⁰ but did not yield significant results with respect to the date of MR imaging scanning. This finding indicates that statistical parametric maps of single subjects reported in our study did not result from systematic shifts of MR imaging parameters with time, but we cannot certainly exclude an influence of unsystematic changes (ie, instability) of MR imaging parameters.

How Many Control Subjects Are Necessary?

Finally, we tried to estimate the effect of smaller control groups. To this end, we repeated all analyses with control groups of 33, 66, and 99



Fig 3. Gray-matter decrease identified in only 1 healthy control subject. Axial and coronal sections of the only matched control subject with GM decrease identified (matched control subject 4: age, 50; sex, male) are displayed by the maximum intensity projection (*column A*), by the projection onto the normalized averaged T1-image (*B1* and *C1*), and, to enable visual inspection, by the individual T1-weighted image (*B2* and *C2*). The numbers in the upper right corner indicate the MNI coordinates. All images are displayed at a significance threshold (voxel level) of *P* less than .05 corrected (FDR).



Fig 4. Influence of the size of the control group. Histograms illustrate the influence of different sizes of the control group (33, 66, 99, and 133) on sensitivity and cluster size. All groups were matched for age and sex so that mean and SD did not differ significantly. As a measure of sensitivity, we determined the size of the largest cluster overlapping with the striatum. These volumes were assigned to 4 classes: 0, 1 to 99, 1000 to 9999, and more than 9999 voxels. Basically, the same results are obtained with control groups of 66, 99, and 133 subjects. With a control group of 33, fewer patients are identified, though a considerable proportion of patients is still detected.

subjects. All groups were matched for age and sex so that mean and SD did not differ significantly from the control group of 133 subjects. To estimate sensitivity, we determined the size of the largest cluster overlapping with the striatum for each single-patient analysis. For comparison of the cluster sizes derived from different numbers of control subjects, the volumes were assigned to 4 classes (0, 1–99, 1000–9999, >9999 voxels) and plotted against the percentage of patients.

Results

Statistical parametric maps on the basis of an ANCOVA model yielded sensitive and biologically plausible results. An overview on the percentage of patients with regional GM decrease identified (at the single-subject level) is given in Fig 1. Examples of single-subject analyses of 4 patients are shown in Fig 2. Ordering the patients with HD according to the motor symptoms from highest to lowest severity, regional GM decrease within the head of the caudate nucleus was identified in patients 1 through 6 and patients 8 through 16. Moreover, more widespread GM decrease that largely comprised the insula was identified in patients 1 through 5 (Fig 2, Panels A and B). It is interesting that the incidental finding of an atrophic right temporal pole in combination with an arachnoidal cyst in patient 6 was clearly detected (Fig 2, Panel C). In the matched control subjects, GM decrease was found in only 1 subject (Fig 3).

Figure 4 shows the results of the single-patient analyses with smaller control groups. Basically, the same results were obtained with control groups of 66, 99, and 133 subjects. With a control group of 33 subjects, fewer patients and smaller clusters were identified.

Discussion

This study aimed to deliver biologically plausible statistical parametric maps of single subjects in early stages of a neurodegenerative disorder by the use of VBM. An ANCOVA model with a pooled estimate of variance revealed GM decrease accentuated in the head of the caudate nucleus in most of the patients with HD, whereas GM decrease of the cortical areas varied from patient to patient (Fig 1), which both fit well with the known pattern of GM decrease in HD. Furthermore, the analysis revealed GM decrease in only 1 of the 22 matched control subjects as expected from the probability of type I error. Although atrophy can be detected by visual inspection in patient 5 (Fig 2, Panel A) and may be assumed in more patients, the sensitivity of the single-subject analysis was clearly superior to visual inspection.

Because a scanner-specific control group of 133 subjects is difficult to obtain, we tried to estimate the effect of smaller control groups. To this end, we repeated all analyses with control groups of 33, 66, and 99 subjects and found that control groups of 66, 99, and 133 subjects resulted in a comparable sensitivity. On the other hand, a considerable proportion of patients could still be detected with only 33 subjects but with a lower sensitivity (Fig 4).

Against this background, VBM in single subjects with suspected neurodegenerative disorder may serve as a diagnostic tool. Moreover, hypotheses with regard to subgroups of certain conditions may be derived from those analyses. Assuming, for example, that one half of a group displays GM change whereas the other half does not, the comparison of the whole group with a control group is likely to miss this GM change. Single-subject analyses of the whole group may reveal such a subgroup so that a new hypothesis can be generated, which, then, can be confirmed in another sample of subjects.

Nevertheless, analysis of VBM data from single subjects, as it stands, has both current and intrinsic limitations. Although this approach potentially enables a hypothesis-free wholebrain analysis of single subjects, the capability of this approach has currently been demonstrated in only 2 neurodegenerative disorders, namely semantic dementia¹⁴ and HD. In subjects with other conditions, however, variability of regional GM may largely overlap with the variability in healthy control subjects and, therefore, hamper detection of GM changes at the single-subject level. Therefore, studies on single subjects with other conditions are necessary to further evaluate the sensitivity of VBM in single subjects with suspected neurodegenerative disorders. Moreover, intrinsic limitations result from the fact that VBM at the single-subject level (as proposed here) is univariate in nature. GM images of single subjects are analyzed exclusively with regard to the normal range (estimated from a sample of healthy control subjects) in a voxel-wise manner so that more specific conclusions cannot be drawn from those data alone. On the other hand, multivariate techniques potentially enable specific conclusions on the nature of GM decrease in single subjects, but these techniques require a clear hypothesis on the condition of the single subject under investigation and the respective group data (derived from a sample of patients compared with a sample of healthy control subjects). Insofar, VBM at the single-subject level may serve as a screening tool. Dependent on the condition assumed and on the group data available, consecutive multivariate tools may then be applied to gain more specific information.

In conclusion, our data demonstrate biologically plausible statistical parametric maps of regional GM decrease at the single-subject level in early HD. Studies of other neurodegenerative disorders are needed to further assess the potential of VBM in single subjects with suspected neurodegenerative disorder.

Acknowledgments

We thank Helga Gräfin von Einsiedel and her colleagues from the Institut für Röntgendiagnostik (Klinikum rechts der Isar, Technische Universität München) for having made this study possible.

References

- Bonilha L, Montenegro MA, Rorden C, et al. Voxel-based morphometry reveals excess gray matter concentration in patients with focal cortical dysplasia. *Epilepsia* 2006;47:908–15
- Bruggemann JM, Wilke M, Som SS, et al. Voxel-based morphometry in the detection of dysplasia and neoplasia in childhood epilepsy: combined grey/ white matter analysis augments detection. *Epilepsy Res* 2007;77:93–101
- Colliot O, Bernasconi N, Khalili N, et al. Individual voxel-based analysis of gray matter in focal cortical dysplasia. *Neuroimage* 2006;29:162–71
- Gitelman DR, Ashburner J, Friston KJ, et al. Voxel-based morphometry of herpes simplex encephalitis. *Neuroimage* 2001;13:623–31
- Huppertz HJ, Grimm C, Fauser S, et al. Enhanced visualization of blurred gray-white matter junctions in focal cortical dysplasia by voxel-based 3D MRI analysis. *Epilepsy Res* 2005;67:35–50
- Kassubek J, Huppertz HJ, Spreer J, et al. Detection and localization of focal cortical dysplasia by voxel-based 3-D MRI analysis. *Epilepsia* 2002;43:596–602
- Merschhemke M, Mitchell TN, Free SL, et al. Quantitative MRI detects abnormalities in relatives of patients with epilepsy and malformations of cortical development. Neuroimage 2003;18:642–49
- Salmenpera TM, Symms MR, Rugg-Gunn FJ, et al. Evaluation of quantitative magnetic resonance imaging contrasts in MRI-negative refractory focal epilepsy. *Epilepsia* 2007;48:229–37
- Wilke M, Kassubek J, Ziyeh S, et al. Automated detection of gray matter malformations using optimized voxel-based morphometry: a systematic approach. *Neuroimage* 2003;20:330–43
- Mehta S, Grabowski TJ, Trivedi Y, et al. Evaluation of voxel-based morphometry for focal lesion detection in individuals. *Neuroimage* 2003;20:1438–54
- Good CD, Johnsrude IS, Ashburner J, et al. A voxel-based morphometric study of ageing in 465 normal adult human brains. *Neuroimage* 2001;14:21–36

- Ashburner J, Friston KJ. Voxel-based morphometry-the methods. Neuroimage 2000;11:805–21
- Salmond CH, de Haan M, Friston KJ, et al. Investigating individual differences in brain abnormalities in autism. *Philos Trans R Soc Lond B Biol Sci* 2003;358:405–13
- Mummery CJ, Patterson K, Price CJ, et al. A voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory. Ann Neurol 2000;47:36–45
- MacDonald ME. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. *Cell* 1993;72:971–83
- Douaud G, Gaura V, Ribeiro MJ, et al. Distribution of grey matter atrophy in Huntington's disease patients: a combined ROI-based and voxel-based morphometric study. Neuroimage 2006;32:1562–75
- Jech R, Klempir J, Vymazal J, et al. Variation of selective gray and white matter atrophy in Huntington's disease. Mov Disord 2007;22:1783–89
- Kassubek J, Juengling FD, Ecker D, et al. Thalamic atrophy in Huntington's disease co-varies with cognitive performance: a morphometric MRI analysis. *Cereb Cortex* 2005;15:846–53
- Kassubek J, Juengling FD, Kioschies T, et al. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry 2004;75:213–20
- 20. Kipps CM, Duggins AJ, McCusker EA, et al. Disgust and happiness recognition correlate with anteroventral insula and amygdala volume respectively in preclinical Huntington's disease. J Cogn Neurosci 2007;19:1206–17
- Mühlau M, Gaser C, Wohlschläger AM, et al. Striatal gray matter loss in Huntington's disease is leftward biased. Mov Disord 2007;22:1169–73
- Mühlau M, Weindl A, Wohlschläger AM, et al. Voxel-based morphometry indicates relative preservation of the limbic prefrontal cortex in early Huntington disease. J Neural Transm 2007;114:367–72
- Peinemann A, Schuller S, Pohl C, et al. Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J Neurol Sci 2005;239:11–19
- Rosas HD, Hevelone ND, Zaleta AK, et al. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. *Neurology* 2005;65:745–47
- Rosas HD, Koroshetz WJ, Chen YI, et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. *Neurology* 2003;60:1615–20
- Ruocco HH, Bonilha L, Li LM, et al. Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat. J Neurol Neurosurg Psychiatry 2008;79:130–35
- 27. Ruocco HH, Lopes-Cendes I, Li LM, et al. **Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat**. *Braz J Med Biol Res* 2006;39:1129–36
- Thieben MJ, Duggins AJ, Good CD, et al. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 2002;125:1815–28
- Wolf RC, Vasic N, Schonfeldt-Lecuona C, et al. Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from eventrelated fMRI. Brain 2007;130:2845–57
- Henson R. Comparing a single patient versus a group of controls. 2006. Available at: http://www.mrc-cbu.cam.ac.uk/people/rik.henson/personal/Henson_ Singlecase_06.pdf
- Crawford JR. Comparing an individual's test score against norms derived from small samples. Clin Neuropsychol 1998;12:482–86
- 32. Signorini M, Paulesu E, Friston K, et al. Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: a clinical validation of statistical parametric mapping. *Neuroimage* 1999;9:63–80
- 33. Good CD, Johnsrude I, Ashburner J, et al. Cerebral asymmetry and the effects of sex and handedness on brain structure: a voxel-based morphometric analysis of 465 normal adult human brains. *Neuroimage* 2001;14:685–700
- 34. Taki Y, Goto R, Evans A, et al. Voxel-based morphometry of human brain with age and cerebrovascular risk factors. *Neurobiol Aging* 2004;25:455–63
- 35. Ashburner J, Friston KJ. Unified segmentation. Neuroimage 2005;26:839-51
- 36. Cuadra MB, Cammoun L, Butz T, et al. Comparison and validation of tissue modelization and statistical classification methods in T1-weighted MR brain images [published erratum appears in *IEEE Trans Med Imaging* 2006;25:241]. *IEEE Trans Med Imaging* 2005;24:1548–65
- Salmond CH, Ashburner J, Vargha-Khadem F, et al. Distributional assumptions in voxel-based morphometry. *Neuroimage* 2002;17:1027–30
- Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B (Methodological) 1995;57:289–300
- Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. *Neuroimage* 2002; 15:870-78
- Nunnemann S, Wohlschläger AM, Gaser C, et al. Accelerated aging of the putamen in men but not in women. Neurobiol Aging 2009;30:147–51